Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-06 20:45:55 - browse：746

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Unique patient identifier: Experts argue the benefits, pitfalls

WSS

Readout LOUD podcast: possible new ALS drug, artificial wombs

The Biogen Aduhelm mess could happen again

Second xenotransplant done with gene

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Readout LOUD podcast: possible new ALS drug, artificial wombs

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Microbiome research is starting to find links to chronic diseases

The high cost of giving birth even with insurance

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Wildfire smoke exposes gaps in outdoor worker protections

Adopting new red light myopia treatments may be short

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biotech lab space demand falls sharply

Medicare proposal to cover medical devices draws a mixed reaction

What Congress can do to address the rural doctor shortage

focus

CommonSpirit Health keeps growing, even as it loses money

Intarcia’s device

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Padmanee Sharma of MD Anderson at center of lawsuit over credit

What’s missing from the debate over nursing home staff minimums

Thermo Fisher plant for manufacturing gene therapies to expand

entertainment

knowledge

Wikipedia

hotspot